2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatment
2018
HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system
Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care 2018, 30: 1282-1289. PMID: 29527934, PMCID: PMC6085161, DOI: 10.1080/09540121.2018.1447079.Peer-Reviewed Original ResearchConceptsPrEP implementation programsPre-exposure prophylaxisHIV risk behaviorsPrEP awarenessHIV pre-exposure prophylaxisRisk behaviorsPersonal HIV riskPrEP care continuumPrEP-eligible womenHepatitis C infectionPrimary care providersHIV risk perceptionUnsafe injection practicesMeeting eligibility criteriaPrison/jailCross-sectional surveyRecent transactional sexLifetime substance usePrEP eligibleC infectionEligible womenCare continuumHIV riskCare providersHigh risk